Glucose transporter 1 (GLUT1) is widely distributed throughout various tissues and contributes to insulin-independent basal glucose uptake. Using a split-ubiquitin membrane yeast two-hybrid system, we newly identified 4F2 heavy chain (4F2hc) as a membrane protein interacting with GLUT1. Though 4F2hc reportedly forms heterodimeric complexes between amino acid transporters, such as LAT1 and LAT2, and regulates amino acid uptake, we investigated the effects of 4F2hc on GLUT1 expression and the associated glucose uptake. First, FLAG-tagged 4F2hc and hemagglutinin-tagged GLUT1 were overexpressed in human embryonic kidney 293 cells and their association was confirmed by coimmunoprecipitation. The green fluorescent protein-tagged 4F2hc and DsRed-tagged GLUT1 showed significant, but incomplete, colocalization at the plasma membrane. In addition, an endogenous association between GLUT1 and 4F2hc was demonstrated using mouse brain tissue and HeLa cells. Interestingly, overexpression of 4F2hc increased the amount of GLUT1 protein in HeLa and HepG2 cells with increased glucose uptake. In contrast, small interfering RNA (siRNA)-mediated 4F2hc gene suppression markedly reduced GLUT1 protein in both cell types, with reduced glucose uptake. While GLUT1 mRNA levels were not affected by overexpression or gene silencing of 4F2hc, GLUT1 degradation after the addition of cycloheximide was significantly suppressed by 4F2hc overexpression and increased by 4F2hc siRNA treatment. Taken together, these observations indicate that 4F2hc is likely to be involved in GLUT1 stabilization and to contribute to the regulation of not only amino acid but also glucose metabolism.
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4F2 heavy chain; glucose transporter 1; glucose uptake GLUCOSE IS A MAJOR SOURCE of energy for nearly all living organisms, and the system for its efficient transport into cells is highly conserved from simple bacteria to mammalian cells. The facilitative glucose transporters (GLUTs) constitute an energy-independent system that transports D-glucose down a concentration gradient. GLUT1, the first GLUT identified, was purified from the red blood cell membrane and has a structure consisting of 12 transmembrane domains that delineate six extracellular loops (26) . Since the discovery of GLUT1, another 13 GLUT isoforms, which are involved in glucose or fructose transport, have been identified in mammals. Among the isoforms identified to date, GLUT1 is widely distributed throughout nearly all tissues and is generally present in the plasma membrane regardless of whether stimulation is delivered. In addition, since it possesses a high affinity for D-glucose, GLUT1 is regarded as contributing mainly to basal glucose uptake. Elevated GLUT1 expression has been shown in many cancers (3, 37) . Oncogenes such as Ras and Src have been shown to upregulate GLUT1 expression (4, 9) . In addition, hypoxiainducible factor 1 , c-Myc, Akt, and estrogen have been shown to induce GLUT1 expression (11, 36) . In contrast, the mechanism regulating the intrinsic activity or stability of GLUT remains largely unknown.
In this study, on the basis of the hypothesis that certain protein(s) bind to and alter the function of GLUT1, we attempted to identify a protein binding with GLUT proteins. Since the conventional yeast two-hybrid system is not suitable for detecting interactions between membrane proteins, we employed the newly developed split-ubiquitin membrane yeast two-hybrid system, which allows the interactions between an integral membrane protein and its partner(s) to be detected (38) . Interestingly, screening using GLUT1 as bait yielded the cDNA encoding the heavy chain (hc) of 4F2, 4F2hc (CD98). 4F2hc reportedly forms a complex with LAT1 or LAT2, and this heterodimer (LAT1/4F2hc) functions as an amino acid transporter at the plasma membrane (14, 31, 33, 35) . Herein, we show that 4F2hc also associates with GLUT1 and contributes to GLUT1 stability, leading to increased glucose transport activity into cells.
MATERIALS AND METHODS
Anti-4F2hc antibody was generated by immunization of rabbits with the glutathione S-transferase-fused COOH-terminal 103 amino acids of human 4F2hc. Anti-FLAG tag and anti-hemagglutinin (HA) tag antibodies were purchased from Sigma-Aldrich (St. Louis, MO). Anti-GLUT1 antibody was from Fabgennix (Mississauga, ON, Canada). Anti-LAT1, anti-4F2hc (mouse), anti-insulin R␤, and anti-LexA antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-rabbit and anti-mouse horseradish peroxidase-conjugated antibodies were obtained from GE Healthcare (Buckinghamshire, UK). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum were purchased from Invitrogen (Carlsbad, CA). 3FLAG-4F2hc cDNA was provided by Yoshikatsu Kanai. All other reagents were of analytical grade.
Split-ubiquitin membrane yeast two-hybrid screening system. DUALmembrane kit 3 (Dualsystems Biotech), the split-ubiquitin membrane yeast two-hybrid system, was used to identify the protein associating with GLUT1. Briefly, in this system, the bait is fused to the COOH-terminal half of ubiquitin (Cub) and the artificial transcription factor LexA-VP16. The prey is fused to the mutated NH 2-terminal half of ubiquitin (NubG). If the bait and prey interact, split ubiquitins are reconstituted and recognized by ubiquitin-specific proteases. Then, the artificial transcription factor consisting of Cub and LexA-VP16 is released and moves to the nucleus, leading to reporter gene activation (Fig. 1A) .
Rabbit GLUT1 cDNA was inserted into the expression vector pBT3-STE to generate the fusion bait with the split ubiquitin and an artificial transcriptional factor (Cub-LexA-VP16) to the COOH terminus of GLUT1. Mouse heart cDNA library, inserted into a pDL2xN-SUC/pDL2xN-STE vector, was purchased from Dualsystems Biotech, and then screened. Bait and the mouse heart cDNA library were transformed into yeast strain NMY51. The HIS3 reporter construct was assayed by growth on SD-Trp-Leu-His-Ade drop-out plates supplemented with 2.5 mM 3-amino-1,2,4-triazole (Wako). Qualitative assessment of the lacZ reporter was conducted using filter lift galactosidase assays (8) .
Cell culture, expression vectors, adenovirus generation, and small interfering RNA transfections. HepG2 hepatoma cells, HeLa cells, and human embryonic kidney (HEK293) cells were grown in DMEM containing 10% fetal calf serum at 37°C in 5% (vol/vol) CO 2 in air. Rabbit GLUT1-HA, rat GLUT4-HA, rabbit GLUT1-DsRed, human LAT1-DsRed, green fluorescent protein (GFP)-human 4F2hc, and human 4F2hc were inserted into cloning sites in the mammalian expression vector pcDNA3 (Invitrogen), as reported previously (34) . Transfection of these expression vectors was performed by the lipofection method using FuGENE 6 (Roche Applied Science, Indianapolis, IN). Recombinant adenovirus, encoding mouse 4F2hc, was generated according to the instruction manual of the Adenovirus Dual Expression Kit (TaKaRa Bio). Adenovirus encoding LacZ served as a control.
The small interfering RNA (siRNA) against 4F2hc was purchased from Invitrogen (Stealth/siRNA duplex oligoribonucleotides), and the transfection of this siRNA was performed using Lipofectamine RNAiMAX (Invitrogen).
Immunoprecipitation and immunoblotting. Whole cell extracts were prepared from HEK293 cells overexpressing 3FLAG-4F2hc, GLUT1-HA, or GLUT4-HA in lysis buffer [50 mM Tris·HCl, pH 7.5, 150 mM NaCl, 10% (wt/vol) glycerol, 100 mM NaF, 10 mM EGTA, 1 mM Na3VO4, 1% (wt/vol) Triton X-100, 5 M ZnCl2, 2 mM phenylmethylsulfonyl fluoride (PMSF), 10 g/ml aprotinin, and 1 g/ml leupeptin]. Cell extracts were incubated for 4 h at 4°C with the HA antibody and then for 1 h with 30 l of protein G-Sepharose beads. The pellets were washed five times with 1 ml of lysis buffer, resuspended in Laemmli sample buffer, and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
HeLa cells were preincubated with 2.5 mM DSP (Thermo Scientific) for 30 min. Male mice, 9 wk of age, were obtained from the Nippon Bio-Supply Center (Tokyo, Japan). All animal studies were conducted according to the Japanese guidelines for the care and use of experimental animals, and the experimental protocols were approved by the Committee of Research Facilities for Laboratory Animal Science, Natural Science Center for Basic Research and Development (N-BARD), University of Hiroshima. For preparation of the membrane fraction, HeLa cells and mouse whole brains were homogenized with homogenizing buffer (0.25 M sucrose, 10 mM Tris, 1 mM EDTA). After filtration through a nylon membrane, the lysates were centrifuged at 600 g for 10 min, and the supernatant was centrifuged at 3,000 g for 10 min. Then, the supernatant was centrifuged at 30,000 g for 30 min, and the pellet was resuspended in 10 mM Tris, 1 mM EDTA, at pH 7.4.
The 4F2hc antibody (90 g) or control IgG (90 g) was covalently coupled to 20 l of IPeX beads (Gene Bio-Application) and stabilized for 30 min at room temperature. Then, the solubilized membrane fraction (200 g in 200 l) was incubated with 5 l of anti-4F2hc-coupled or anti-IgG-coupled beads for 4 h at 4°C. The beads were extensively washed, and the immunoprecipitated proteins were eluted in Laemmli buffer and resolved by SDS-PAGE.
Western blot analysis was carried out as described previously (34) . In brief, equal amounts of protein lysates were separated by SDS-PAGE and electrophoretically transferred to polyvinylidene difluoride membranes in a transfer buffer consisting of 20 mM Tris·HCl, 150 mM glycine, and 20% methanol. The membranes were blocked with 3% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 and incubated with specific antibodies, followed by incubation with horseradish peroxidase-conjugated secondary antibodies. The antigen-antibody interactions were visualized by incubation with ECL chemiluminescence reagent (GE Healthcare).
Measurement of 2-deoxyglucose and leucine uptakes. The 2-deoxy-D-[
3 H]glucose uptake assay was performed as described previously (2) . HeLa or HepG2 cells were incubated in serum-free DMEM for 2 h, rapidly washed at 37°C with KRP buffer (in mM: 128 NaCl, 4.7 KCl, 1.25 CaCl2, 1.25 MgSO4, 10 NaHPO4, pH 7.4), and 450 l of KRP buffer were then added to each well. The measurements of 2-deoxyglucose uptake were initiated by addition of 50 l of 2-deoxy-D-[1, 2- 3 H]glucose, so that each well contained 0.4 Ci and 0.1 mM 2-deoxyglucose. After a 5-min incubation at 37°C, 1 ml of ice-cold phosphate-buffered saline (PBS) containing 10 mM glucose and 0.3 mM phloretin was added, and the cells were rapidly washed three times with ice-cold PBS containing 10 mM glucose and subsequently solubilized by adding SDS (final concentration, 0.05%). Aliquots of the solubilized extract were assayed for radioactivity using a liquid scintillation counter.
The 14 C]L-leucine, the uptake reaction was terminated by removing the uptake solution followed by washing four times with ice-cold uptake solution.
GLUT1 degradation assay. To observe GLUT1 degradation, 10 g/l cycloheximide, an inhibitor of protein synthesis, was added as indicated in RESULTS and figure legends. The GLUT1 expression level was measured by immunoblotting at the indicated time after the addition of cycloheximide. A lysosome inhibitor, chloroquine, 20 M (Wako), and a proteasome inhibitor, MG-132, 10 M (Sigma Aldrich), were added to HeLa cells, and their effects on GLUT1 degradation were also examined.
Immunostaining. HeLa cells were fixed with 4% paraformaldehyde for 10 min, rinsed with PBS, and then exposed to 0.2% Triton X-100 in PBS for 5 min. The cells were subsequently incubated for 1 h at room temperature with anti-GLUT1 rabbit antibody (1:100) and anti-4F2hc mouse antibody (1:50). After being washed with PBS five times, FITC-labeled anti-rabbit IgG (1:100) and Cy3-labeled antimouse IgG (1:100) were added as the secondary antibodies. Immunofluorescence was visualized with a laser-scanning confocal imaging system.
RNA analysis. RNA extractions were carried out using TRIzol followed by purification over a QIAEASY RNA column. Reverse transcription and quantitative PCR were carried out as already described. Amplifications of GLUT1 and GAPDH cDNAs were performed using the Opticon Monitor (version 3; Bio-Rad). Cycling conditions comprised a 3-min denaturation step at 95°C, followed by 40 cycles of denaturation (95°C for 15 s), annealing (60°C for 30 s), and extension (72°C for 30 s). After amplification, melting curve analysis was performed. Each sample was amplified in triplicate.
The primer sets for human (h)GLUT1 were TCACTGTGCTC-CTGGTTCTG and CCTGTGCTCCTGAGAGATCC (233 bp) and for hGAPDH were ACCACAGTCCATGCCATCAC and TCCACCAC-CCTGTTGCTGTA (451 bp).
Statistical analysis. Results are expressed as means Ϯ SE, and statistical comparisons among groups were carried out using Student's t-test, unless otherwise indicated.
RESULTS

Identification of 4F2hc, as a novel membrane protein interacting with GLUT1
, by the split-ubiquitin membrane yeast two-hybrid system. As bait, full-length GLUT1 was fused to the COOH-terminal half of ubiquitin (Cub) and artificial transcription factors. Expression of the bait in yeast was confirmed by immunoblotting against LexA (Fig. 1B) . A mouse heart muscle cDNA library, fused to the mutated NH 2 -terminal half of ubiquitin (NubG), was screened with the above-mentioned GLUT1 cDNA construct. After the exclusion of nonspecific positive clones, we newly identified 4F2hc as a membrane protein interacting with GLUT1. 4F2hc and GLUT1 coexpressing yeast proliferated in the selective plate (Fig. 1C) and exhibited robust ␤-galactosidase activity (Fig. 1D) , indicating an interaction between 4F2hc and GLUT1 in yeast.
4F2hc associates and colocalizes with GLUT1. First, FLAGtagged 4F2hc and either HA-tagged GLUT1 or HA-tagged GLUT4 were overexpressed in HEK293 cells and their associations were examined by coimmunoprecipitation ( Fig. 2A) . Fig. 1 . Using the split-ubiquitin yeast two-hybrid system, 4F2hc was newly identified as a membrane protein interacting with glucose transporter 1 (GLUT1). A: split-ubiquitin yeast-two hybrid system. Full-length GLUT1 is fused to the COOH-terminal half of ubiquitin (Cub) and the artificial transcription factor LexA-VP16. Mouse heart muscle cDNA library is fused to the mutated NH2-terminal half of ubiquitin (NubG). B: expression of GLUT1 as bait in yeast. Yeast was subjected to protein extraction before separation of proteins by SDS-PAGE. C: yeast coexpressed with Nub-4F2hc and either Alg5-Cub-LexA-VP16 or GLUT1-Cub-LexA-VP16 was incubated on a selective plate for 72 h. D: color development in a ␤-galactosidase assay.
HA-tagged GLUT1 but not GLUT4 was detected in the FLAGtagged 4F2hc immunoprecipitate. Next, we examined the association between endogenous GLUT1 and 4F2hc in HeLa cells and mouse brain, employing coimmunoprecipitation (Fig.  2B ). GLUT1 was detected by the anti-4F2hc antibody, but not control IgG, in membrane fraction immunoprecipitates. The positive control, LAT1 in the anti-4F2hc antibody immunoprecipitate, was also confirmed in both HeLa cells and mouse brain.
Then, GFP-tagged 4F2hc and DsRed-tagged GLUT1 were transfected into HeLa cells, and colocalization of GLUT1 or LAT1 with 4F2hc was investigated. Considerable amounts of these GFP-tagged proteins appeared to be aggregated near nuclei and within intracellular vesicles, but LAT1 as well as GLUT1 apparently exhibited significant colocalization with 4F2hc at the plasma membrane and intracellular sites (Fig. 2C) . In addition, endogenous GLUT1 and 4F2hc in HeLa cells were coimmunostained with anti-GLUT1 and anti-4F2hc antibodies (Fig. 2D ). Although these staining data do not convincingly demonstrate an association between GLUT1 and 4F2hc, their colocalization at the plasma membrane raises this possibility.
Overexpression of 4F2hc increases glucose uptake. Since 4F2hc is likely to interact with GLUT1, the effect of 4F2hc on glucose transport activity was examined. 4F2hc reportedly regulates the functions of amino acid transporters, and increased 4F2hc expression enhances amino acid uptake. First, 4F2hc was overexpressed in HeLa cells, and the uptakes of 2-deoxyglucose and leucine were measured. Overexpression of 4F2hc increased glucose uptake in an expression level-dependent manner, by up to 55%, and leucine uptake was similarly increased (Fig. 3B) . Interestingly, 4F2hc overexpression also increased the amount of GLUT1 protein (Fig. 3A) . Since the transfection efficiency of the 4F2hc encoding plasmid in HepG2 cells was not sufficient, we employed adenovirusmediated 4F2hc overexpression for HepG2 cells. Overexpression of 4F2hc by adenovirus in HepG2 cells also increased glucose uptake and the amount of GLUT1 protein (Fig. 3, C  and D) .
Knockdown of 4F2hc decreases glucose uptake and GLUT1 expression level. To further investigate the role of 4F2hc in glucose uptake, we performed loss of function analyses. Treatment with 4F2hc siRNA but not control siRNA reduced the 4F2hc protein expression level by ϳ90% (Fig. 4, A and C, left) . Importantly, 4F2hc siRNA treatment also markedly reduced GLUT1 protein in both HeLa and HepG2 cells (right graphs of Fig. 4, A and C) , with reduced glucose uptake (left graphs of Fig. 4, B and D) . The altered transport activities of glucose caused by 4F2hc overexpression or siRNA treatment are generally very similar to those of leucine (right graphs of Fig. 3 , B and C, and Fig. 4, B and D) . To exclude the possibility of off-target effects of the siRNA knockdown experiments, we reintroduced a siRNA-resistant version of 4F2hc (siRNA is human; overexpressed 4F2hc is mouse). Reconstitution of mouse 4F2hc reversed the siRNA-mediated GLUT1 reduction (Supplemental Fig. S1A ; Supplemental Material for this article is available online at the Journal website). In contrast, suppression of 4F2hc did not affect the expression of insulin R␤ (Supplemental Fig. S1B ).
Enhanced green fluorescent protein (EGFP)-conjugated GLUT1 ligand, which has a receptor-binding domain in common with human T cell leukemia virus envelope glycoprotein, allows the amount of GLUT1 localized at the plasma membrane to be monitored by fluorescence staining (23, 24) . Using this EGFP-conjugated ligand, we assessed the GLUT1 amount at the plasma membrane under conditions of either 4F2hc overexpression or knockdown in HeLa cells. The siRNAmediated gene silencing of 4F2hc resulted in a reduction of the cell surface GLUT1 expression level, while 4F2hc overexpression produced an increase (Fig. 4E) .
4F2hc is involved in GLUT1 stabilization and prevents GLUT1 from undergoing lysosomal degradation. To explore the mechanism underlying 4F2hc-related alterations in GLUT1 expression, we examined the mRNA levels of GLUT1 at 24 h and 48 h after the initiation of 4F2hc overexpression or 4F2hc siRNA transfection. Neither overexpression nor knockdown of 4F2hc significantly affected the mRNA levels of GLUT1 (Fig. 5,  A and B) . Since these observations indicate that 4F2hc does not regulate the transcriptional level of GLUT1, we considered the possibility that 4F2hc enhances GLUT1 stability and thereby increases glucose transport activity. The mechanism by which GLUT1 is degraded has not been elucidated in detail, but it has been shown that the lysosomal pathway contributes to GLUT1 degradation (30) . GLUT1 degradation was investigated at the indicated period after addition of cycloheximide, an inhibitor of protein synthesis. Overexpression of 4F2hc significantly suppressed the GLUT1 degradation rate (Fig. 5C ). On the other hand, the siRNA-mediated reduction in 4F2hc markedly increased the GLUT1 degradation rate, as compared with treatment with control siRNA (Fig.  5D) . As previously reported, GLUT1 degradation was confirmed to be abolished by chloroquine, an agent suppressing lysosomal degradation (Fig. 5E) (32) . In fact, it was shown that the proteasome blocker MG-132 did not stabilize GLUT1, which is consistent with previous reports (32) . Taken together, our results strongly suggest that 4F2hc stabilizes GLUT1 by protecting it from lysosomal degradation.
DISCUSSION
In the present study, we newly demonstrated 4F2hc to be a protein interacting with GLUT1. 4F2hc, a membrane protein consisting of 529 amino acids and containing a single membrane-spanning domain, was initially identified as a lymphocyte activation antigen (13) . 4F2hc reportedly forms a heterodimeric complex with specific light chain subunits of amino acid transporters such as LAT1 and LAT2 (14, 31, 33, 35) . The heterodimer consisting of LAT1 or LAT2 and 4F2hc moves to the cell surface and exerts both neutral and basic amino acid transporter activity (25, 27) . A previous study using deletion mutants revealed the domain of LAT1 indispensable for the association with 4F2hc to be the most NH 2 -terminal transmembrane domain, and that a disulfide bridge connects their extracellular domains (5). A similar structure has been reported for the lactate transporter, which consists of 12 membrane-spanning monocarboxylate transporter 1 (MCT1) or MCT4 and a single membrane-spanning CD147 (20) .
Given that GLUT1 has a similar structure, i.e., 12 putative membrane-spanning domains, similar to those of LAT1/2 and MCT1/4, we considered an association of 4F2hc with GLUT1 to be likely. We thus carried out experiments to assess this possibility. Indeed, the association between GLUT1 and 4F2hc was confirmed not only by coimmunoprecipitation of the overexpressed proteins, but also endogenously in HeLa cells and mouse brain, although it is unclear what percentage of GLUT1 is present as a heterodimer form with 4F2hc. While 4F2hc has a disulfide bridge between LAT1 with a cysteine on the extracellular side immediately after the transmembrane domain (5) , this cysteine residue is not conserved in GLUT1, indicating that the association between GLUT1 and 4F2hc is not mediated by such a disulfide bond, but rather is simply noncovalent. Since the disulfide bridge connecting the extracellular domains of LAT1/2 and 4F2hc is not reportedly essential for association, the association between GLUT1 and 4F2hc without a disulfide bridge is not surprising (6, 27) . However, in contrast to the essential role of 4F2hc in LAT1 or . E: 4F2hc or GLUT1 was overexpressed or small interfering RNA against 4F2hc (si4F2hc) was transfected into HeLa cells for 24 h. Enhanced GFP (EGFP)-conjugated GLUT1 ligand (AbCys, Paris, France) was added, and after a 30-min incubation, cell surface GLUT1 was observed by fluorescent microscopy. RNAi, RNA interference. Data are expressed as means Ϯ SE (n ϭ 4). *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001, compared with negative controls.
LAT2 transport activity, GLUT1 can transport D-glucose without forming a complex with 4F2hc, an observation supported by previous reports showing the reconstitution of purified GLUT1 to an artificially constructed lectin membrane, as well as GLUT1 overexpression experiments in oocytes (15, 16, 17) . Although we can speculate that heterodimeric complex formation with 4F2hc affects the kinetics of GLUT1 glucose transport activity to some degree, we were not able to clarify this issue herein because of difficulty measuring the percentages of GLUT1 alone and GLUT1/4F2hc forms.
On the other hand, it was clearly demonstrated that 4F2hc increases the amount of GLUT1 not only in whole cells but also at the plasma membrane. GLUT1 has been regarded as being involved in basal glucose uptake, and cells with high proliferative activity generally have high GLUT1 contents as shown in many cancers, fetal tissues, and the placenta (1, 22) . We examined whether the 4F2hc expression level regulates not only amino acid transport activity via an association with LAT1, but also glucose transport activity via that with GLUT1. We found that 4F2hc overexpression increased not only leucine but also glucose uptake, while siRNA-mediated gene suppression of 4F2hc decreased these uptakes in HeLa and HepG2 cells (Figs. 3 and 4) . GLUT1 expression is elevated in highly proliferative cells. Oncogenes such as Ras and Src reportedly raise GLUT1 expression at the transcriptional level (4, 9) . However, taking our results into consideration, the rate of GLUT1 degradation is also involved in regulation of the GLUT1 amount, and 4F2hc protects GLUT1 from lysosomal degradation. In addition, 4F2hc expression is also reportedly elevated in many cancers, suggesting its activity to correlate with cell proliferation and continuous growth (10, 19, 21, 28, 29) . Thus, such growth-promoting stimuli not only increase GLUT1 synthesis at the transcriptional level, but also decrease the degradation of GLUT1 via upregulated 4F2hc. Previous reports described posttranscriptional modifications of GLUT1, such as monoubiquitinylation or sentrin conjugation, and their significance. These modifications reportedly regulate GLUT1 protein stability and cell function (7, 12) . Thus, GLUT1 stability appears to also be important for determining both basal glucose uptake and cell proliferation. Taken together, these observations may support the hypothesis that increased expression of 4F2hc leads to an increased GLUT1 protein amount via suppression of GLUT1 degradation, resulting in the increased basal glucose uptake necessary for the progression of malignancy. In fact, the expression levels of both GLUT1 and 4F2hc are reportedly elevated in many cancers and correlate with tumor progression (10, 28, 39) . Further study is necessary to test our hypothesis.
In summary, our observations indicate that 4F2hc is likely to be involved in GLUT1 stabilization and to contribute to the regulation of not only amino acid but also glucose metabolism, both of which contribute to the incorporation of nutrients into highly proliferative cells. In this regard, the inhibition of 4F2hc may be regarded as a novel potential target for anticancer drugs.
